The Bell2Bell (B2B) Podcast

Bell2Bell’s latest podcast features Beau Kelley, CEO of diversified real estate holding company Mountain Top Properties Inc. (OTC: MTPP), and Joseph Kelley, CEO of full service real estate management company On Site Builder Construction Co. Inc.

To begin the interview, Beau Kelley introduced Mountain Top Properties and its business model.

“This company is really focused on two main sectors, which are real estate/real property development and property technology,” Beau Kelley said. “We see that the property technology side of things is really a massive, growing opportunity to be able to expedite finance and payment methods and shipping routes and so many things that we can help out from a logistics standpoint. On the real estate side, this has been an opportunity that my father and I have talked about for a long time – bringing the capital markets opportunities into his building business.”

Joseph Kelley then discussed On Site Builder Construction and its history.

“We're approaching our 45th year building in the Hamptons. I've had the pleasure to work with some of the most renowned designers, interior designers and architects, building a custom home portfolio… Our houses have been highlighted in many publications and social media contacts and magazines and so forth. We have always had a tremendous reputation of building on time and on budget, even in the very high-end market.”

Beau Kelley then provided some insight into the real estate market of the Hamptons.

“The real estate market here is already a very well-known, high-end market… and there are not enough of these high-end homes available on the market to satisfy demand. So, although there are some opportunities to be able to redevelop existing projects, there are fantastic opportunities in ground-up homes. What we do is identify the lot and the area that we want to be in – waterfront and water view are really the premium areas to be. We're really looking forward to being able to get going with two or three projects in the new year, because we see that being just a fantastic way to build shareholder value and partner value over time.”

Join IBN’s Stuart Smith, CEO Beau Kelley of Mountain Top Properties Inc. and CEO Joseph Kelley of On Site Builder Construction Co. Inc. to learn more about the history of Mountain Top Properties.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

 

Bell2Bell’s latest podcast features Beau Kelley, CEO of diversified real estate holding company Mountain Top Properties Inc. (OTC: MTPP), and Joseph Kelley, CEO of full service real estate management company On Site Builder Construction Co. Inc.

To begin the interview, Beau Kelley introduced Mountain Top Properties and its business model.

“This company is really focused on two main sectors, which are real estate/real property development and property technology,” Beau Kelley said. “We see that the property technology side of things is really a massive, growing opportunity to be able to expedite finance and payment methods and shipping routes and so many things that we can help out from a logistics standpoint. On the real estate side, this has been an opportunity that my father and I have talked about for a long time – bringing the capital markets opportunities into his building business.”

Joseph Kelley then discussed On Site Builder Construction and its history.

“We're approaching our 45th year building in the Hamptons. I've had the pleasure to work with some of the most renowned designers, interior designers and architects, building a custom home portfolio… Our houses have been highlighted in many publications and social media contacts and magazines and so forth. We have always had a tremendous reputation of building on time and on budget, even in the very high-end market.”

Beau Kelley then provided some insight into the real estate market of the Hamptons.

“The real estate market here is already a very well-known, high-end market… and there are not enough of these high-end homes available on the market to satisfy demand. So, although there are some opportunities to be able to redevelop existing projects, there are fantastic opportunities in ground-up homes. What we do is identify the lot and the area that we want to be in – waterfront and water view are really the premium areas to be. We're really looking forward to being able to get going with two or three projects in the new year, because we see that being just a fantastic way to build shareholder value and partner value over time.”

Join IBN’s Stuart Smith, CEO Beau Kelley of Mountain Top Properties Inc. and CEO Joseph Kelley of On Site Builder Construction Co. Inc. to learn more about the history of Mountain Top Properties.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

Bell2Bell’s latest podcast features Bruce Nurse, Head of Investor Relations for Vision Marine Technologies Inc. (NASDAQ: VMAR), a global leader and innovator within the performance electric recreational boating industry.

To begin the interview, Nurse introduced Vision Marine Technologies and its business model.

“Our objective here – our mission if you like – is really to disrupt the traditional boating industry by transforming the boating experience with electric power,” Nurse said. “We all see what's happening with the auto industry, with electrification of our vehicles. Every auto manufacturer now has an option for the consumer to drive electric, but we haven't seen this on the water.”

Bell2Bell’s latest podcast features Bruce Nurse, Head of Investor Relations for Vision Marine Technologies Inc. (NASDAQ: VMAR), a global leader and innovator within the performance electric recreational boating industry.

To begin the interview, Nurse introduced Vision Marine Technologies and its business model.

“Our objective here – our mission if you like – is really to disrupt the traditional boating industry by transforming the boating experience with electric power,” Nurse said. “We all see what's happening with the auto industry, with electrification of our vehicles. Every auto manufacturer now has an option for the consumer to drive electric, but we haven't seen this on the water.”

Bell2Bell’s latest podcast features Mariano Soria, General Manager of Turbo Energy S.A., a leading photovoltaic energy storage technology company based in Valencia, Spain.

To begin the interview, Soria introduced Turbo Energy and its business model.

“Turbo Energy is part of a group with more than 20 years of experience in photovoltaic energy,” Soria said. “The company itself was born 10 years ago with the aim of introducing disruptive storage technology, mainly for off-grid homes that wanted to live with photovoltaic energy. It was the introduction of lithium-ion batteries in Spain, and it was also, for us, the beginning of Turbo Energy's leadership in Spain concerning photovoltaic energy storage.”

Bell2Bell’s latest podcast features Mariano Soria, General Manager of Turbo Energy S.A., a leading photovoltaic energy storage technology company based in Valencia, Spain.

To begin the interview, Soria introduced Turbo Energy and its business model.

“Turbo Energy is part of a group with more than 20 years of experience in photovoltaic energy,” Soria said. “The company itself was born 10 years ago with the aim of introducing disruptive storage technology, mainly for off-grid homes that wanted to live with photovoltaic energy. It was the introduction of lithium-ion batteries in Spain, and it was also, for us, the beginning of Turbo Energy's leadership in Spain concerning photovoltaic energy storage.”

Bell2Bell’s latest podcast features Wa’el Hashad, CEO of Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty.

To begin the interview, Hashad introduced Longeveron and its business model.

“Longeveron is a cell therapy-based biotech company. It was established in 2014 as a spin-off from a technology that was developed at the University of Miami School of Medicine by a renowned scientist and cardiologist, Dr. Josh Hare,” Hashad said. “Josh has been working since he graduated medical school… on trying to help patients regenerate their heart muscles after heart attacks. He continued to use stem cells – specifically mesenchymal stem cells, or medicinal signaling cells – to try to develop medicines that may help patients have a better outcome after heart attacks and so on.”

Bell2Bell’s latest podcast features Wa’el Hashad, CEO of Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty.

To begin the interview, Hashad introduced Longeveron and its business model.

“Longeveron is a cell therapy-based biotech company. It was established in 2014 as a spin-off from a technology that was developed at the University of Miami School of Medicine by a renowned scientist and cardiologist, Dr. Josh Hare,” Hashad said. “Josh has been working since he graduated medical school… on trying to help patients regenerate their heart muscles after heart attacks. He continued to use stem cells – specifically mesenchymal stem cells, or medicinal signaling cells – to try to develop medicines that may help patients have a better outcome after heart attacks and so on.”

In this engaging episode, David Hough shared key updates following PaxMedica's recent meeting with the FDA, highlighting pivotal achievements such as:

• FDA discussion of PaxMedica's data from the PAX-HAT 301 Study and comprehensive nonclinical programs.
• PAX-HAT-301 study confirmed as positive evidence for African Sleeping Sickness treatment, expected to result in substantial time and resource savings for PaxMedica.
• FDA acknowledgment of PaxMedica's comprehensive nonclinical program, including safety pharmacology, ADME, and toxicology studies.
• Waivers granted for the thorough QT/QTc studies, affirming data relevance to the patient population.
• 2024 NDA submission anticipation underscores PaxMedica's commitment to neglected tropical disease treatments.

 

In this engaging episode, David Hough shared key updates following PaxMedica's recent meeting with the FDA, highlighting pivotal achievements such as:

• FDA discussion of PaxMedica's data from the PAX-HAT 301 Study and comprehensive nonclinical programs.
• PAX-HAT-301 study confirmed as positive evidence for African Sleeping Sickness treatment, expected to result in substantial time and resource savings for PaxMedica.
• FDA acknowledgment of PaxMedica's comprehensive nonclinical program, including safety pharmacology, ADME, and toxicology studies.
• Waivers granted for the thorough QT/QTc studies, affirming data relevance to the patient population.
• 2024 NDA submission anticipation underscores PaxMedica's commitment to neglected tropical disease treatments.